Welcome to our dedicated page for Stryker Corporation news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker Corporation stock.
Stryker Corporation, based in Kalamazoo, Michigan, is an American multinational renowned for its groundbreaking medical technologies. The company designs, manufactures, and markets a wide array of medical equipment and devices that play critical roles in healthcare settings around the globe.
Stryker's comprehensive product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds, gurneys, and spinal devices. The company is a dominant force in the medical sector, holding a top-three position in reconstructive orthopedic implants and leading in operating room equipment.
In the most recent financial updates, Stryker reported impressive operating results for the fourth quarter and the full year of 2023. With organic sales growth exceeding 11% and surpassing $20 billion in sales, the company has shown robust performance. Kevin Lobo, Chair and CEO, attributes this success to the dedicated teams driving high growth and strong adjusted earnings.
Stryker's influence extends globally, impacting over 150 million patients annually through its work in MedSurg, Neurotechnology, Orthopaedics, and Spine. Just over a quarter of its total revenue is generated from markets outside the United States, highlighting its international presence and reach.
The company continues to innovate and expand its horizons. For instance, Stryker will disclose its financial results for the first quarter of fiscal year 2024 on April 30, 2024. This forthcoming report is anticipated to provide further insights into the company’s financial health and ongoing projects.
For those interested in staying updated, Stryker's press releases and financial disclosures are readily available on their website. The corporation maintains a strong commitment to improving healthcare outcomes and enhancing patient care through its innovative products and services.
Stryker (NYSE: SYK) announced an extension for its cash tender offer for Wright Medical Group N.V. (NASDAQ: WMGI) shares, now set to expire on November 10, 2020. As of October 23, 2020, approximately 12.4% of Wright's shares have been tendered. The completion of the tender offer is contingent upon various conditions outlined in the Schedule TO filed with the SEC. Shareholders who have already tendered do not need to take further action. For more details, shareholders are advised to contact Innisfree M&A Incorporated.
Stryker (NYSE: SYK) announced an extension of its cash tender offer for Wright Medical Group (NASDAQ: WMGI). The new expiration is set for October 28, 2020. As of October 12, 2020, approximately 10.7% of Wright's outstanding shares, or 13,870,057 shares, were tendered. The completion of this offer is subject to conditions outlined in previous filings with the SEC. Shareholders who have tendered do not need to act again due to this extension. Innisfree M&A Incorporated serves as the information agent for the tender offer.
Stryker (NYSE: SYK) has extended the offering period for its cash tender offer for Wright Medical Group N.V. (NASDAQ: WMGI) shares until October 14, 2020. As of September 28, 2020, 13,817,681 Wright Medical shares, about 10.6% of the outstanding shares, had been validly tendered. The tender offer is subject to the conditions in the Schedule TO filed with the SEC. Shareholders who already tendered do not need to act again. Stryker is a leading medical technology company focused on improving healthcare outcomes.
Stryker (NYSE: SYK) announced an extension of its cash tender offer for all outstanding shares of Wright Medical Group N.V. (NASDAQ: WMGI). The offer period is now set to expire on October 14, 2020, unless further extended. As of September 28, 2020, approximately 10.6% of Wright Medical's ordinary shares had been validly tendered. The completion of the tender offer is contingent upon various conditions as outlined in the Schedule TO filed with the SEC. Shareholders do not need to take further action if they have already tendered their shares.
Stryker (NYSE:SYK) will host a conference call on October 29, 2020, at 4:30 p.m. ET to discuss its Q3 2020 operating results and provide an operational update. The final results will be released at 4:05 p.m. ET on the same day. Interested participants can join the call by dialing (877) 702-4565 for domestic calls or (647) 689-5532 for international calls, using conference ID 5297589. A webcast will be available on Stryker's website, which will also host archived recordings of the call from October 29, 2020, 8:00 p.m. ET until November 5, 2020, 11:59 p.m. ET.
Stryker (NYSE:SYK) will host a conference call on October 29, 2020, at 4:30 p.m. ET, to discuss its operating results for the quarter ended September 30, 2020. The final results will be released at 4:05 p.m. on the same day. To join the call, dial (877) 702-4565 domestically or (647) 689-5532 internationally, using conference ID 5297589. A webcast will be available on their website, and the call will be archived for later access until November 5, 2020.
Stryker (NYSE: SYK) will participate in the Morgan Stanley 18th Annual Virtual Global Healthcare Conference on September 15, 2020, at 10:15 a.m. Eastern Time. Kevin Lobo, the Chairman and CEO, will represent the company. A webcast and replay of the presentation will be accessible on Stryker's website, www.stryker.com, and archived on the Investor Relations page. Stryker is a leader in medical technology, focusing on improving healthcare through innovative products in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Stryker (NYSE: SYK) has extended the cash tender offer for Wright Medical Group N.V. (NASDAQ: WMGI) shares, now set to expire on September 30, 2020. As of August 27, 2020, approximately 10.5% of Wright Medical's ordinary shares were validly tendered. The tender offer's completion is contingent on certain conditions outlined in Stryker's filings with the SEC. Shareholders who have already tendered their shares do not need to take further action due to this extension. Innisfree M&A Incorporated serves as the information agent for the tender offer, with contact information provided.
Stryker reported a significant net sales decrease of 24.3% for Q2 2020, totaling $2.8 billion, attributable to COVID-19 impacts, including postponed medical procedures. Adjusted EPS fell 67.7% to $0.64, while reported EPS decreased by 117.5% to ($0.22). All business segments, including Orthopaedics and MedSurg, faced declines. The company projects continued negative effects from the pandemic, limiting financial outlook and guidance.
Stryker (NYSE: SYK) has declared a quarterly dividend of $0.575 per share, payable on October 30, 2020, to shareholders on record as of September 30, 2020. This dividend represents an increase of approximately 11% compared to the previous year, although it remains unchanged from the last quarter. Stryker continues to lead in the medical technology sector, offering innovative solutions across Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, aimed at improving patient and hospital outcomes.
FAQ
What is the current stock price of Stryker Corporation (SYK)?
What is the market cap of Stryker Corporation (SYK)?
What does Stryker Corporation specialize in?
Where is Stryker Corporation headquartered?
How did Stryker perform financially in 2023?
What is the scope of Stryker's global impact?
What are some of the products offered by Stryker?
When will Stryker report its financial results for Q1 2024?
How can I access Stryker's financial reports?
Who should I contact for investor inquiries at Stryker?
What areas does Stryker focus its innovations on?
How can I stay updated with Stryker's latest developments?
